$151 Million is the total value of Lynx1 Capital Management LP's 18 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 77.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CABA | Sell | CABALETTA BIO INC | $32,053,320 | +13.8% | 2,106,000 | -3.5% | 21.20% | +14.9% |
| ALPN | Sell | ALPINE IMMUNE SCIENCES INC | $27,532,830 | +0.3% | 2,404,614 | -10.0% | 18.21% | +1.2% |
| MRUS | Sell | MERUS N V | $27,122,306 | -10.6% | 1,150,225 | -0.2% | 17.94% | -9.8% |
| CBAY | Sell | CYMABAY THERAPEUTICS INC | $14,822,941 | +12.3% | 994,161 | -17.5% | 9.80% | +13.4% |
| TSCAN THERAPEUTICS INC | $13,374,976 | +2.4% | 5,224,600 | 0.0% | 8.85% | +3.4% | ||
| GHRS | Buy | GH RESEARCH PLCordinary shares | $11,086,939 | -3.6% | 1,103,178 | +13.8% | 7.33% | -2.7% |
| STOK | New | STOKE THERAPEUTICS INC | $6,738,007 | – | 1,710,154 | +100.0% | 4.46% | – |
| AUTL | New | AUTOLUS THERAPEUTICS PLCspon ads | $3,175,848 | – | 1,363,025 | +100.0% | 2.10% | – |
| PIRS | PIERIS PHARMACEUTICALS INC | $2,913,203 | +80.1% | 9,775,849 | 0.0% | 1.93% | +81.8% | |
| KNTE | Sell | KINNATE BIOPHARMA INC | $2,795,808 | -55.0% | 1,997,006 | -2.5% | 1.85% | -54.5% |
| SLN | New | SILENCE THERAPEUTICS PLCads | $2,315,428 | – | 235,787 | +100.0% | 1.53% | – |
| New | BIONOMICS LIMITEDads | $2,201,882 | – | 815,512 | +100.0% | 1.46% | – | |
| CCCC | New | C4 THERAPEUTICS INC | $1,895,768 | – | 1,019,230 | +100.0% | 1.25% | – |
| Sell | THESEUS PHARMACEUTICALS INC | $1,889,496 | -73.2% | 702,415 | -7.2% | 1.25% | -73.0% | |
| NKTR | New | NEKTAR THERAPEUTICS | $1,052,315 | – | 1,766,815 | +100.0% | 0.70% | – |
| PASG | Sell | PASSAGE BIO INC | $125,102 | -88.6% | 190,124 | -83.7% | 0.08% | -88.5% |
| New | ZURA BIO LTD | $65,452 | – | 9,917 | +100.0% | 0.04% | – | |
| DBVT | DBV TECHNOLOGIES S Asponsored adr | $24,840 | -28.4% | 18,265 | 0.0% | 0.02% | -30.4% | |
| CMPS | Exit | COMPASS PATHWAYS PLCsponsored ads | $0 | – | -20,114 | -100.0% | -0.11% | – |
| PHVS | Exit | PHARVARIS N V | $0 | – | -21,225 | -100.0% | -0.21% | – |
| ATHA | Exit | ATHIRA PHARMA INC | $0 | – | -193,573 | -100.0% | -0.37% | – |
| Exit | STRUCTURE THERAPEUTICS INCsponsored ads | $0 | – | -23,000 | -100.0% | -0.63% | – | |
| CGEM | Exit | CULLINAN ONCOLOGY INC | $0 | – | -115,063 | -100.0% | -0.81% | – |
| NLTX | Exit | NEOLEUKIN THERAPEUTICS INC | $0 | – | -3,094,554 | -100.0% | -1.68% | – |
| Exit | PARDES BIOSCIENCES INC | $0 | – | -3,902,434 | -100.0% | -4.63% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MERUS N V | 8 | Q3 2023 | 21.9% |
| ALPINE IMMUNE SCIENCES INC | 8 | Q3 2023 | 20.2% |
| CYMABAY THERAPEUTICS INC | 8 | Q3 2023 | 10.0% |
| THESEUS PHARMACEUTICALS INC | 8 | Q3 2023 | 5.6% |
| PIERIS PHARMACEUTICALS INC | 8 | Q3 2023 | 5.8% |
| KINNATE BIOPHARMA INC | 7 | Q3 2023 | 18.0% |
| PARDES BIOSCIENCES INC | 7 | Q2 2023 | 11.0% |
| PASSAGE BIO INC | 7 | Q3 2023 | 4.0% |
| BELLUS HEALTH INC NEW | 6 | Q1 2023 | 22.7% |
| CABALETTA BIO INC | 4 | Q3 2023 | 22.6% |
View Lynx1 Capital Management LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-23 |
| SC 13G | 2024-04-01 |
| SC 13G | 2024-03-29 |
| SC 13G | 2024-02-16 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Lynx1 Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.